-
公开(公告)号：US11439592B2
公开(公告)日：2022-09-13
申请号：US17210696
申请日：2021-03-24
Applicant: Ocular Therapeutix, Inc.
Inventor： Charles D. Blizzard , Arthur Driscoll , Rami El-Hayek , Michael Goldstein , Joseph Iacona , Peter Jarrett , Timothy S. Jarrett , Erica Kahn , Zachary Lattrell
IPC: A61K9/00 , A61K9/06 , A61K31/4439 , A61K47/34 , A61P27/02 , A61K31/4427 , A61K45/06
Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
-
公开(公告)号：US20230040637A1
公开(公告)日：2023-02-09
申请号：US17880175
申请日：2022-08-03
Applicant: Ocular Therapeutix, Inc.
Inventor： Peter Jarrett , Rami El-Hayek , Timothy S. Jarrett , Zachary Lattrell , Arthur Driscoll , Charles D. Blizzard
IPC: A61K9/00 , A61K31/4439
Abstract: Provided herein are sustained-release biodegradable ocular hydrogel implants which are useful in the treatment of certain ocular conditions.
-
公开(公告)号：US11622935B2
公开(公告)日：2023-04-11
申请号：US17673265
申请日：2022-02-16
Applicant: OCULAR THERAPEUTIX, INC.
Inventor： Charles D. Blizzard , Ankita Desai , Arthur Driscoll , Michael Goldstein
IPC: A61K9/00 , A61K9/14 , A61K31/5575 , C08L67/04 , A61K47/69 , A61P27/06 , A61K31/216 , A61K47/10
Abstract: The present invention relates to the treatment of ocular diseases in a human subject In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.
-
公开(公告)号：US20210308043A1
公开(公告)日：2021-10-07
申请号：US17210696
申请日：2021-03-24
Applicant: Ocular Therapeutix, Inc.
Inventor： Charles D. Blizzard , Arthur Driscoll , Rami El-Hayek , Michael Goldstein , Joseph Iacona , Peter Jarrett , Timothy S. Jarrett , Erica Kahn , Zachary Lattrell
IPC: A61K9/00 , A61K9/06 , A61K31/4439 , A61K47/34
Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
-
公开(公告)号：US20200337990A1
公开(公告)日：2020-10-29
申请号：US16857464
申请日：2020-04-24
Applicant: Ocular Therapeutix, Inc.
Inventor： Michael Goldstein , Arthur Driscoll , Charles D. Blizzard , Ankita Desai
IPC: A61K9/00 , A61K31/215 , A61P27/06 , A61P27/02
Abstract: Provided herein are sustained release biodegradable ocular hydrogel implants which are useful for lowering ocular pressure and for treating related conditions.
-
Patent Agency Ranking
公开(公告)号：US20230118774A1
公开(公告)日：2023-04-20
申请号：US17991762
申请日：2022-11-21
Applicant: Ocular Therapeutix, Inc.
Inventor： Charles D. Blizzard , Arthur Driscoll , Rami El-Hayek , Michael Goldstein , Joseph Iacona , Peter Jarrett , Timothy S. Jarrett , Erica Kahn , Zachary Lattrell
IPC: A61K9/00 , A61K9/06 , A61K31/4427 , A61K47/34 , A61P27/02 , A61K31/4439
Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
-
公开(公告)号：US20240285518A1
公开(公告)日：2024-08-29
申请号：US18583383
申请日：2024-02-21
Applicant: Ocular Therapeutix, Inc.
Inventor： Peter Jarrett , Rami El-Hayek , Timothy S. Jarrett , Zachary Lattrell , Arthur Driscoll , Charles D. Blizzard
IPC: A61K9/00 , A61K31/4439
CPC classification number: A61K9/0024 , A61K9/0051 , A61K31/4439
Abstract: Provided herein are sustained-release biodegradable ocular hydrogel implants which are useful in the treatment of certain ocular conditions.
-
公开(公告)号：US20240165018A1
公开(公告)日：2024-05-23
申请号：US18384564
申请日：2023-10-27
Applicant: OCULAR THERAPEUTIX, INC.
Inventor： Michael Goldstein , Arthur Driscoll , Charles D. Blizzard , Ankita Desai
IPC: A61K9/00 , A61K31/215 , A61P27/02 , A61P27/06
CPC classification number: A61K9/0024 , A61K9/0051 , A61K31/215 , A61P27/02 , A61P27/06
Abstract: Provided herein are sustained release biodegradable ocular hydrogel implants which are useful for lowering ocular pressure and for treating related conditions.
-
公开(公告)号：US20230285281A1
公开(公告)日：2023-09-14
申请号：US18081229
申请日：2022-12-14
Applicant: OCULAR THERAPEUTIX, INC.
Inventor： Charles D. Blizzard , Ankita Desai , Arthur Driscoll , Michael Goldstein
IPC: A61K9/00 , A61K9/14 , A61K31/5575 , C08L67/04 , A61K47/69 , A61P27/06 , A61K31/216 , A61K47/10
CPC classification number: A61K9/0051 , A61K9/146 , A61K31/5575 , C08L67/04 , A61K47/6903 , A61K47/6937 , A61P27/06 , A61K9/0048 , A61K31/216 , A61K47/10 , C08L2201/06 , C08L2312/00
Abstract: The present invention relates to the treatment of ocular diseases in a human subject. In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.
-
公开(公告)号：US11534396B2
公开(公告)日：2022-12-27
申请号：US17744189
申请日：2022-05-13
Applicant: Ocular Therapeutix, Inc.
Inventor： Charles D. Blizzard , Arthur Driscoll , Rami El-Hayek , Michael Goldstein , Joseph Iacona , Peter Jarrett , Timothy S. Jarrett , Erica Kahn , Zachary Lattrell
IPC: A61K9/00 , A61K9/06 , A61K31/4439 , A61P27/02 , A61K31/4427 , A61K47/34 , A61K45/06
Abstract: This invention relates to methods of treatment with a sustained release biodegradable ocular implant containing a tyrosine inhibitor dispersed in a hydrogel.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.011 seconds)
